PARKINSUN communication aid to support patient-centered Parkinson's care
Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN
This project will test whether using the PARKINSUN communication tool during GP and neurologist visits helps people with Parkinson's disease get more patient-centered care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Trial ID | NCT04179695 on ClinicalTrials.gov |
What this trial studies
PARKINSUN is a brief communication aid intended to structure conversations between people with Parkinson's and their physicians. In this randomized intervention, adult patients with PD are assigned to bring and use PARKINSUN during routine consultations or to continue usual consultations without the tool. Visits occur every three months over a seven-month period and comparisons focus on measures of communication quality and care coordination. Participants must be able to attend in-person visits and meet basic cognitive and language criteria for participation.
Who should consider this trial
Good fit: Adults with Parkinson's disease of any stage who can attend regular GP or neurology visits, speak French, are cognitively intact (MoCA >22), and can give informed consent are ideal candidates.
Not a fit: People with significant cognitive impairment, major psychiatric or neurological comorbidities, those under legal guardianship, unable to attend visits, or not fluent in French are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, PARKINSUN could improve patient–physician communication and lead to more personalized and coordinated care for people with Parkinson's disease.
How similar studies have performed: Communication aids have produced benefits in other chronic conditions, but evidence specifically demonstrating impact in Parkinson's disease is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult men and women with all stages of PD * Without severe chronic neurological or mental or psychiatric pathology * Absence of cognitive impairment affecting autonomy (MDS criteria of dementia and MOCA \> 22) * able to come (alone or accompanied) to consultation * Affiliate or beneficiary of a social security scheme * Subject having signed informed consent * Patient willing to comply with all procedures of the study and its duration Exclusion Criteria: * Administrative reasons: impossibility of receiving informed information, inability to participate in the whole study, absence of coverage by the social security system, refusal to sign consent. * Subject under tutelage or curtailer. * Subject not fluent in the French language to understand the instructions necessary to carry out the cognitive tests.
Where this trial is running
Lille
- Hopital Roger Salengro, CHU Lille — Lille, France (Recruiting)
Study contacts
- Principal investigator: David Devos — University Hospital, Lille
- Study coordinator: David Devos, MD,PhD
- Email: david.devos@chru-lille.fr
- Phone: 03 20 44 54 49
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.